Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 901 clinical trials
Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients

This is a pilot study using cytotoxic T lymphocytes (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Gamma-capture system will be effective in decreasing specific viral load in patients with BK virus viremia and BK virus-associated symptoms post-allogeneic hematopoietic stem cell transplantation (HSCT), renal transplantation, and chemotherapy.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

The purpose of the CliniMACS TCR-Biotin System and CliniMACS CD19 is to improve the safety and efficacy of allogeneic HLA-partially matched related or unrelated donors HSCT when no matched donors are available, to treat malignant and nonmalignant disorders for which HSCT is the recommended best available therapy.

immunosuppression
cardiovascular disease
graft versus host disease
cancer
hla-drb1
  • 0 views
  • 19 Feb, 2024
  • 1 location
Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT

This single arm, prospective study on the feasibility of a bridging treatment with low-dose azacitidine (AZA) in combination with short term CAG derived regimen prior to allogeneic stem cell transplantation (allo-HSCT) in patients with advanced myelodysplastic syndromes (MDS) .

myelodysplastic syndromes
azacitidine
allogeneic hematopoietic stem cell transplant
cell transplantation
stem cell transplantation
  • 0 views
  • 19 Feb, 2024
  • 1 location
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

Thus adding bortezomib, may improve the remission rate, thus bridging to allogeneic stem cell transplant. Adding bortezomid in the relapsed chemotherapy protocol may increase the toxicity and even treatment related mortality.

proteasome inhibitor
leukemic cells
bortezomib injection
acute lymphoblastic leukemia
cns involvement
  • 0 views
  • 19 Feb, 2024
  • 1 location
Flu-Bu-Mel Conditioning Regimen for Myeloid Disease

For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing allo-HSCT, the conditioning regimen will be 5-day Fludarabine, 2-day Busulifan and 2-day melphalan

  • 0 views
  • 19 Feb, 2024
  • 2 locations
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) with LentiGlobin BB305 Drug Product for SCD.

priapism
pediatric
karnofsky performance status
gene therapy
analgesia
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag

Background Diamond-Blackfan anemia (DBA) is treated with steroids. But some people cannot take steroids, or steroids don t work. Other patients must get blood transfusions regularly which are time consuming and can have significant side effects. The drug eltrombopag can increase red blood cells. Researchers want to see if it …

corticosteroids
cell counts
anemia
eltrombopag
blood cell count
  • 0 views
  • 19 Feb, 2024
  • 1 location
Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD

Therapy of severe intestinal graft-versus-host disease (GVHD) despite the introduction of novel target agents is associated with worse outcome compared to the other forms. Response to steroids is observed only in about 10% of patients. The most promising approaches are JAK inhibition and fecal microbiota transplantation. In this pilot study …

acute graft-versus-host disease
graft versus host disease
ruxolitinib
  • 0 views
  • 19 Feb, 2024
  • 1 location
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R or Chronic Myelomonocytic Leukemia-2 (CMML-2)

This is a Phase III multi-center, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to azacitidine in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who have an indication for treatment with azacitidine in first-line …

cmml-2
azacitidine
cell transplantation
chronic myelomonocytic leukemia
myelomonocytic leukemia
  • 0 views
  • 19 Feb, 2024
  • 23 locations
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Treatment options for older adults with Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS) are limited. Although stem cell transplantation remains one of the most effective treatments it is associated with severe side effects which have until recently prevented its use in older adults.

secondary aml
conditioning therapies
acute myeloid leukemia
behavioral intervention
cell transplantation
  • 0 views
  • 19 Feb, 2024
  • 1 location